Luke Halpern is an assistant editor with Pharmacy Times. Luke wrote for Pharmacy Times in the summer of 2023, and assumed a full-time role in June 2024. His work has been featured in Pharmacy Times and the American Journal of Managed Care. He graduated from the University of Massachusetts, Amherst in May 2024.
Thimerosal Reenters Public Debate as ACIP Scrutinizes Use in Influenza Vaccines
June 27th 2025With the Advisory Committee on Immunization Practices recommending that adults receive thimerosal-free influenza vaccines, the preservative that was phased out of most childhood vaccines in 2001 has reentered the public eye.
Read More
Chronic IVIG Therapy May Reduce Incidence of Cancer, Especially in Patients With CIDP
June 27th 2025Intravenous immunoglobulin (IVIG) use over an extended period in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) was potentially associated with a reduced incidence of cancer over time, although more research is necessary.
Read More
ACIP Recommends Adults Receive Seasonal, Single-Dose Influenza Vaccines Free of Thimerosal
June 26th 2025The Advisory Committee on Immunization Practices (ACIP) voted 5-1, with 1 voter abstaining, to recommend that adults receive seasonal influenza vaccines that do not contain the preservative thimerosal.
Read More
Cholesterol-Lowering Drugs May Significantly Increase Risk of Diabetic Microvascular Complications
June 24th 2025HMGCR inhibitors were found to significantly increase the risk of experiencing microvascular complications in patients with diabetes, while NPC1L1 inhibitors were found to reduce the risk.
Read More
IVIG-Glucocorticoid Combination Therapy Reduces Need for Adjunctive Immunotherapy in Pediatric MIS-C
June 23rd 2025Glucocorticoids alone were found to reduce treatment failure and fever duration, but the combination with intravenous immunoglobulin (IVIG) significantly reduced the need for adjunctive immunotherapy following treatment.
Read More
Midyear Roundup: FDA’s Novel Oncology Drug Approvals in 2025
June 18th 2025In the first half of 2025, the FDA approved 7 novel drugs for oncologic conditions, including for non-small cell lung cancer; ovarian cancer; and metastatic, hormone receptor-positive, human epidermal growth factor 2-negative breast cancer.
Read More
Expert: Strategies for CIDP Medication Adherence and Emerging Treatment Innovations
June 14th 2025Amy Duong, PharmD, BCACP, explains pharmacists' critical role in promoting chronic inflammatory demyelinating neuropathy (CIDP) treatment adherence and staying informed about new therapeutic developments.
Read More
Collaborative Management of Severe Pericarditis: The Role of Pharmacists in Rilonacept Treatment
Pharmacists play a critical role in managing complex pericarditis cases.
Read More
Perioperative Nivolumab Shows Long-Term EFS, Favorable OS in Resectable NSCLC
June 11th 2025Building on positive event-free survival (EFS) and overall survival (OS) rates in the original analysis of CheckMate 77T, new results indicate sustained survival over 3 years following treatment with nivolumab compared with placebo in non-small cell lung cancer (NSCLC).
Read More